ProfileGDS4814 / ILMN_1771264
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 70% 71% 72% 68% 71% 74% 71% 69% 71% 72% 72% 70% 72% 69% 73% 68% 70% 71% 72% 72% 73% 72% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)72.144170
GSM780708Untreated after 4 days (C2_1)77.41971
GSM780709Untreated after 4 days (C3_1)82.553772
GSM780719Untreated after 4 days (C1_2)68.413968
GSM780720Untreated after 4 days (C2_2)77.383871
GSM780721Untreated after 4 days (C3_2)92.134274
GSM780710Trastuzumab treated after 4 days (T1_1)78.002871
GSM780711Trastuzumab treated after 4 days (T2_1)71.481269
GSM780712Trastuzumab treated after 4 days (T3_1)77.527771
GSM780722Trastuzumab treated after 4 days (T1_2)82.388172
GSM780723Trastuzumab treated after 4 days (T2_2)81.031372
GSM780724Trastuzumab treated after 4 days (T3_2)73.214770
GSM780713Pertuzumab treated after 4 days (P1_1)79.806172
GSM780714Pertuzumab treated after 4 days (P2_1)70.313169
GSM780715Pertuzumab treated after 4 days (P3_1)83.975173
GSM780725Pertuzumab treated after 4 days (P1_2)67.765768
GSM780726Pertuzumab treated after 4 days (P2_2)72.083170
GSM780727Pertuzumab treated after 4 days (P3_2)78.219871
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)82.935172
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)82.981572
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)88.498673
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)80.372472
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)75.774271